AstraZeneca PLC [NASDAQ: AZN] closed the trading session at $52.57 on 01/19/21. The day’s price range saw the stock hit a low of $52.21, while the highest price level was $52.66. The company report on January 18, 2021 that ENHERTU® (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer.
First HER2-directed medicine approved for patients with gastric cancer in a decade.
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
The stocks have a year to date performance of 5.16 percent and weekly performance of 3.98 percent. The stock has been moved at -10.41 percent over the last six months. The stock has performed 3.22 percent around the most recent 30 days and changed -0.87 percent over the most recent 3-months.
If compared to the average trading volume of 9.70M shares, AZN reached to a volume of 13560121 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $62.48 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 15, 2021. The new note on the price target was released on December 07, 2020, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 0.99, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.36. The Price to Book ratio for the last quarter was 11.31, with the Price to Cash per share for the same quarter was set at 3.20.
AZN stock trade performance evaluation
AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.98. With this latest performance, AZN shares gained by 3.22% in over the last four-week period, additionally sinking by -10.41% over the last 6 months – not to mention a rise of 2.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 59.71, with the RSI for the last a single of trading hit 69.21, and the three-weeks RSI is set at 54.60 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 52.53, while it was recorded at 51.27 for the last single week of trading, and 53.37 for the last 200 days.
AstraZeneca PLC [AZN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +11.51 and a Gross Margin at +72.35. AstraZeneca PLC’s Net Margin is presently recorded at +5.47.
Return on Total Capital for AZN is now 8.66, given the latest momentum, and Return on Invested Capital for the company is 4.59. Return on Equity for this stock inclined to 10.62, with Return on Assets sitting at 2.23. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 138.85. Additionally, AZN Total Debt to Total Capital is recorded at 58.13, with Total Debt to Total Assets ending up at 29.70. Long-Term Debt to Equity for the company is recorded at 123.54, with the Long-Term Debt to Total Capital now at 51.72.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $14,822 per employee. Receivables Turnover for the company is 4.55 with a Total Asset Turnover recorded at a value of 0.41.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.
Earnings per share (EPS) analysis for AstraZeneca PLC [AZN] stock
With the latest financial reports released by the company, AstraZeneca PLC posted 0.45/share EPS, while the average EPS was predicted by analysts to be reported at 0.59/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 19.40%.
AstraZeneca PLC [AZN]: Insider Ownership positions
There are presently around $21,438 million, or 16.80% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 52,093,683, which is approximately -4.493% of the company’s market cap and around 0.50% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 51,498,061 shares of the stock with an approximate value of $2.71 billion in AZN stocks shares; and FMR LLC, currently with $2.33 billion in AZN stock with ownership of nearly -7.035% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 376 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 17,005,194 shares. Additionally, 272 investors decreased positions by around 37,062,584 shares, while 120 investors held positions by with 353,737,949 shares. The mentioned changes placed institutional holdings at 407,805,727 shares, according to the latest SEC report filing. AZN stock had 116 new institutional investments in for a total of 2,793,153 shares, while 66 institutional investors sold positions of 4,782,881 shares during the same period.